GLP-1 analogues, such as liraglutide (Saxenda), are widely used to treat obesity and diabetes by regulating insulin secretion and food intake, but they have recently been found to increase the risk of acute pancreatitis [4,5]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.